Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

790
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
790
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

3.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.0K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

729
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
729
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

278
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
278
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

825
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
825
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

227
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
227

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thiazides Attenuate the Diuretic Response to Pecavaptan, a Dual Vasopressin Receptor Antagonist, in Patients Hospitalized for Heart Failure.

Journal of cardiac failure·2026
Same author

Pancreatic Involvement During Acute Heart Failure: Insights from the AVANTI trial.

European journal of heart failure·2026
Same author

A multicentre, randomized, double-blind, active and placebo-controlled study of pecavaptan, a dual V1a/V2 vasopressin receptor antagonist, in patients with acute heart failure: The AVANTI trial.

European journal of heart failure·2025
Same author

QT Prolongation and Ventricular Pre-Excitation in Psychiatric Illness: Have We Pre-Excited our Colleagues?

JACC. Case reports·2025
Same author

Predictors of Polymorphic Ventricular Tachycardia and Ventricular Fibrillation in Patients With Takotsubo Syndrome.

The American journal of cardiology·2024
Same author

Rapidly Progressive and Catastrophic Calciphylaxis After Mechanical Valve Replacement: An Anticoagulation Dilemma.

JACC. Case reports·2022
Same journal

REVEALing New Standards: Low Risk Redefined.

JACC. Heart failure·2026
Same journal

Implantable Cardioverter-Defibrillator Therapy in Contemporary Heart Failure Patients: An Analysis From the EMPEROR-Reduced Trial.

JACC. Heart failure·2026
Same journal

Sodium-Glucose Cotransporter 2 Inhibitor Following Left Ventricular Assist Device Implantation: A Randomized Controlled Trial.

JACC. Heart failure·2026
Same journal

Noninvasive Wearable-Based Algorithm to Predict Worsening Heart Failure by Change in Natriuretic Peptide Levels.

JACC. Heart failure·2026
Same journal

Long-Term HM3 Outcomes: Is Age the Signal or the Surrogate?

JACC. Heart failure·2026
Same journal

Impact of Age on Long-Term Clinical Outcomes Following HeartMate 3 LVAD Implantation: Insights From the MOMENTUM 3 Trial.

JACC. Heart failure·2026
See all related articles

Related Experiment Video

Updated: Jan 22, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.0K

Heart Failure With Preserved Ejection Fraction: Types 1 and 2?

Steven R Goldsmith, Mengistu Simegn

    JACC. Heart Failure
    |June 29, 2019
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
    03:42

    Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

    Published on: March 29, 2024

    2.0K
    A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
    07:09

    A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

    Published on: February 18, 2022

    2.3K

    Related Experiment Videos

    Last Updated: Jan 22, 2026

    Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
    09:20

    Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

    Published on: February 13, 2021

    7.0K
    Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
    03:42

    Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

    Published on: March 29, 2024

    2.0K
    A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
    07:09

    A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

    Published on: February 18, 2022

    2.3K